 |
Shinji
Harada [Vice-president, Kumamoto University] |
Opening Remarks | |
| Session
I |
9:10-9:55 〔45〕 |  |
|
| Chair: Hiroaki Mitsuya | |||
 |
O-1-01 |
Michael
D. Miller Merck Research Laboratories, USA |
HIV Drug Discovery: Past, Present, and Future |
| Session
II |
9:55-10:35 〔40〕 |  |
|
| Chair: Shinichi Oka | |||
 |
O-1-02 |
Hiroaki
Mitsuya Kumamoto University, Japan |
Development of HIV-1 Chemotheraputics in the Era of "HIV-1 To Be Defeated" |
| 10:35-10:50
〔15〕 |
Coffee Break | ||
| Session
III |
10:50-12:05 〔75〕 |  |
|
| Chair: Masafumi Takiguchi | |||
 |
O-1-03 |
Tomas
Hanke University of Oxford, UK |
The 2nd generation conserved region mosaic vaccine against HIV-1. |
 |
O-1-04 |
Tetsuro
Matano NIID / Kumamoto University, Japan |
Depletion of vaccine-induced CD107a- CD4+ T cells following SIV infection |
| 12:05-13:30
〔85〕 |
Lunch | ||
| Session
IV |
13:30-14:05 〔35〕 |  |
|
| Chair: Tetsuro Matano | |||
 |
O-1-05 |
Mark
S. de Souza Cooper Human Systems, USA |
T cell dysregulation at the intestinal mucosa and peripheral blood during early acute HIV infection |
| Session
V |
14:05-14:40 〔35〕 |  |
|
| Chair: Nobuo Sakaguchi | |||
 |
O-1-06 |
Yoshio
Koyanagi Kyoto University, Japan |
Conflicts and benefits between primate lentiviruses and host restriction factors |
| Session
VI |
14:40-15:10 〔30〕 |  |
|
| Chair: Hiroyuki Gatanaga | |||
 |
O-1-07 |
Takamasa
Ueno Kumamoto University, Japan |
Impaired Nef function is associated with early control of HIV-1 viremia |
| 15:10-15:25
〔15〕 |
Coffee Break | ||
| Session
VII |
15:25-16:40 〔75〕 |  |
|
| Chair: Yorifumi Satou | |||
 |
O-1-08 |
Mathias
Lichterfeld Harvard Medical School, USA |
Cellular reservoirs for HIV-1 long-term persistence despite antiretroviral therapy |
 |
O-1-09 |
Seiji
Okada Kumamoto University, Japan |
HIV-1 restriction factor COMMD1 reinforces HIV-1 latent infection through IκB-α stabilization. |
| Session
VIII |
16:40-17:10 〔30〕 |  |
|
| Chair: Kazuhisa Yoshimura | |||
 |
O-1-10 |
Hiroyuki
Yamamoto NIID, Japan |
In vivo determinants of SIV neutralizing antibody induction |
| Session
VIII |
17:10-17:40 〔30〕 |  |
|
| Chair: Shinya Suzu | |||
 |
O-1-11 |
Shuzo
Matsushita Kumamoto University, Japan |
Therapeutic application of neutralizing antibodies based on the recent data on complementary and synergistic activities against a wide range of HIV-1 strains. |